tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: InMode (INMD), Fulcrum Therapeutics (FULC) and Amarin (AMRN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on InMode (INMDResearch Report), Fulcrum Therapeutics (FULCResearch Report) and Amarin (AMRNResearch Report).

InMode (INMD)

Robert W. Baird analyst Jeff Johnson reiterated a Buy rating on InMode on January 11 and set a price target of $53.00. The company’s shares closed last Friday at $32.70.

According to TipRanks.com, Johnson is a 5-star analyst with an average return of 18.1% and a 56.6% success rate. Johnson covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Tandem Diabetes Care, and Patterson Companies.

InMode has an analyst consensus of Strong Buy, with a price target consensus of $50.40, representing a 55.6% upside. In a report issued on January 11, Needham also maintained a Buy rating on the stock with a $60.00 price target.

See the top stocks recommended by analysts >>

Fulcrum Therapeutics (FULC)

SVB Securities analyst Joseph Schwartz reiterated a Buy rating on Fulcrum Therapeutics on January 12 and set a price target of $30.00. The company’s shares closed last Friday at $13.70.

According to TipRanks.com, Schwartz is ranked 0 out of 5 stars with an average return of -5.3% and a 41.2% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Mereo Biopharma Group Plc, and Ultragenyx Pharmaceutical.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Fulcrum Therapeutics with a $22.71 average price target, a 62.6% upside from current levels. In a report issued on January 4, Oppenheimer also maintained a Buy rating on the stock.

Amarin (AMRN)

SVB Securities analyst Roanna Ruiz reiterated a Hold rating on Amarin on January 11. The company’s shares closed last Friday at $2.09.

According to TipRanks.com, Ruiz has 0 stars on 0-5 stars ranking scale with an average return of -36.2% and a 19.6% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Enanta Pharmaceuticals, and Xeris Pharmaceuticals.

Amarin has an analyst consensus of Moderate Buy, with a price target consensus of $3.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on INMD:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles